tiprankstipranks
Trending News
More News >
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
US Market

ArriVent BioPharma, Inc. (AVBP) Stock Forecast & Price Target

Compare
28 Followers
See the Price Targets and Ratings of:

AVBP Analyst Ratings

Strong Buy
6Ratings
Strong Buy
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
ArriVent
BioPharma, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AVBP Stock 12 Month Forecast

Average Price Target

$39.83
▲(56.69%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for ArriVent BioPharma, Inc. in the last 3 months. The average price target is $39.83 with a high forecast of $45.00 and a low forecast of $37.00. The average price target represents a 56.69% change from the last price of $25.42.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","46":"$46","22.75":"$22.8","30.5":"$30.5","38.25":"$38.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,22.75,30.5,38.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22,23.76923076923077,25.53846153846154,27.307692307692307,29.076923076923077,30.846153846153847,32.61538461538461,34.38461538461539,36.15384615384615,37.92307692307692,39.69230769230769,41.46153846153846,43.230769230769226,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22,23.37153846153846,24.743076923076924,26.114615384615384,27.486153846153847,28.857692307692307,30.229230769230767,31.60076923076923,32.972307692307695,34.34384615384615,35.715384615384615,37.08692307692307,38.458461538461535,{"y":39.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22,23.153846153846153,24.307692307692307,25.46153846153846,26.615384615384613,27.769230769230766,28.923076923076923,30.076923076923077,31.23076923076923,32.38461538461539,33.53846153846153,34.69230769230769,35.84615384615385,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.98,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.94,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.31,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.69,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.73,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.78,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$39.83Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on AVBP
Soumit RoyJonesTrading
JonesTrading
$40
Buy
57.36%
Upside
Reiterated
06/16/25
Positive Outlook for ArriVent BioPharma Amid Strong Stock Momentum and Anticipated Trial Success
Oppenheimer Analyst forecast on AVBP
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
$39
Buy
53.42%
Upside
Reiterated
06/09/25
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Guggenheim Analyst forecast on AVBP
Michael SchmidtGuggenheim
Guggenheim
$45
Buy
77.03%
Upside
Reiterated
05/15/25
Guggenheim Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
H.C. Wainwright Analyst forecast on AVBP
Robert BurnsH.C. Wainwright
H.C. Wainwright
$39$40
Buy
57.36%
Upside
Reiterated
05/14/25
ArriVent Biopharma price target raised to $40 from $39 at H.C. WainwrightArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright
LifeSci Capital Analyst forecast on AVBP
Sam SlutskyLifeSci Capital
LifeSci Capital
$38
Buy
49.49%
Upside
Reiterated
05/12/25
ArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy Rating
B.Riley Financial Analyst forecast on AVBP
Kalpit PatelB.Riley Financial
B.Riley Financial
$37
Buy
45.55%
Upside
Initiated
03/20/25
ArriVent Biopharma initiated with a Buy at B. RileyArriVent Biopharma initiated with a Buy at B. Riley
Citi
$36
Buy
41.62%
Upside
Reiterated
11/26/24
Citi Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Jefferies Analyst forecast on AVBP
Kelly ShiJefferies
Jefferies
$35
Buy
37.69%
Upside
Assigned
08/15/24
Analysts Offer Insights on NA Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Proficient Auto Logistics, Inc. (NASDAQ: PAL)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
JonesTrading Analyst forecast on AVBP
Soumit RoyJonesTrading
JonesTrading
$40
Buy
57.36%
Upside
Reiterated
06/16/25
Positive Outlook for ArriVent BioPharma Amid Strong Stock Momentum and Anticipated Trial Success
Oppenheimer Analyst forecast on AVBP
Unknown AnalystOppenheimer
Not Ranked
Oppenheimer
$39
Buy
53.42%
Upside
Reiterated
06/09/25
Oppenheimer Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Guggenheim Analyst forecast on AVBP
Michael SchmidtGuggenheim
Guggenheim
$45
Buy
77.03%
Upside
Reiterated
05/15/25
Guggenheim Reaffirms Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
H.C. Wainwright Analyst forecast on AVBP
Robert BurnsH.C. Wainwright
H.C. Wainwright
$39$40
Buy
57.36%
Upside
Reiterated
05/14/25
ArriVent Biopharma price target raised to $40 from $39 at H.C. WainwrightArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright
LifeSci Capital Analyst forecast on AVBP
Sam SlutskyLifeSci Capital
LifeSci Capital
$38
Buy
49.49%
Upside
Reiterated
05/12/25
ArriVent BioPharma: Promising Clinical Developments and Strategic Advancements Justify Buy Rating
B.Riley Financial Analyst forecast on AVBP
Kalpit PatelB.Riley Financial
B.Riley Financial
$37
Buy
45.55%
Upside
Initiated
03/20/25
ArriVent Biopharma initiated with a Buy at B. RileyArriVent Biopharma initiated with a Buy at B. Riley
Citi
$36
Buy
41.62%
Upside
Reiterated
11/26/24
Citi Keeps Their Buy Rating on ArriVent BioPharma, Inc. (AVBP)
Jefferies Analyst forecast on AVBP
Kelly ShiJefferies
Jefferies
$35
Buy
37.69%
Upside
Assigned
08/15/24
Analysts Offer Insights on NA Companies: ArriVent BioPharma, Inc. (NASDAQ: AVBP) and Proficient Auto Logistics, Inc. (NASDAQ: PAL)
Stocks with the Highest Top Analyst Consensus in the General Sector
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ArriVent BioPharma, Inc.

1 Month
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+2.72%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 77.78% of your transactions generating a profit, with an average return of +2.72% per trade.
3 Months
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+14.16%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +14.16% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
5/9 ratings generated profit
56%
Average Return
+5.90%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +5.90% per trade.
2 Years
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+15.13%
assigned a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +15.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AVBP Analyst Recommendation Trends

Rating
Nov 24
Jan 25
Mar 25
May 25
Jun 25
Strong Buy
1
1
4
8
11
Buy
11
9
5
2
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
10
9
10
11
In the current month, AVBP has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AVBP average Analyst price target in the past 3 months is 39.83.
Each month's total comprises the sum of three months' worth of ratings.

AVBP Financial Forecast

AVBP Earnings Forecast

Next quarter’s earnings estimate for AVBP is -$0.68 with a range of -$0.80 to -$0.52. The previous quarter’s EPS was -$1.90. AVBP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 60.35% of the time in the same period. In the last calendar year AVBP has Outperformed its overall industry.
Next quarter’s earnings estimate for AVBP is -$0.68 with a range of -$0.80 to -$0.52. The previous quarter’s EPS was -$1.90. AVBP beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 60.35% of the time in the same period. In the last calendar year AVBP has Outperformed its overall industry.
No data currently available

AVBP Sales Forecast

Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 55.14% of the time in the same period. In the last calendar year AVBP has Preformed in-line its overall industry.
Next quarter’s sales forecast for AVBP is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. AVBP beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 55.14% of the time in the same period. In the last calendar year AVBP has Preformed in-line its overall industry.

AVBP Stock Forecast FAQ

What is AVBP’s average 12-month price target, according to analysts?
Based on analyst ratings, ArriVent BioPharma, Inc.’s 12-month average price target is 39.83.
    What is AVBP’s upside potential, based on the analysts’ average price target?
    ArriVent BioPharma, Inc. has 56.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AVBP a Buy, Sell or Hold?
          ArriVent BioPharma, Inc. has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is ArriVent BioPharma, Inc.’s price target?
            The average price target for ArriVent BioPharma, Inc. is 39.83. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $37.00. The average price target represents 56.69% Increase from the current price of $25.42.
              What do analysts say about ArriVent BioPharma, Inc.?
              ArriVent BioPharma, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of AVBP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis